Searchable abstracts of presentations at key conferences in endocrinology

ea0005p149 | Endocrine Tumours and Neoplasia | BES2003

Usefulness of growth hormone response to a test dose of subcutaneous octreotide in predicting longer-term response to the drug. Poor responses predict the need for adjuvant therapy to achieve 'safe' growth hormone levels

Lindsay J , McConnell E , Hunter S , McCance D , Sheridan B , Atkinson A

From a group of 41 patients with acromegaly, the majority of whom had pituitary surgery as primary therapy, we have compared growth hormone responses to a test dose of octreotide across 8 hours with a 3 year random growth hormone in 22 patients who at the 3 year assessment were receiving at least 600mcg octreotide daily subcutaneously or 20mg LAR monthly intramuscularly and in 2 other patients who had achieved 3 year GH of <5 mU/l on smaller doses. Seven patients had a basa...

ea0004dp32 | Diabetes, metabolism and cardiovascular | SFE2002

Nateglinide effects on the secretion of glycated insulin and glucose tolerance in subjects with Type 2 diabetes

Lindsay J , McKillop A , Mooney M , O'Harte F , Flatt P , Bell P

Aims: Glycated insulin exhibits impaired glucose-lowering ability and increasing evidence supports a role for glycation of insulin in the insulin resistant state of Type 2 diabetes. We used a novel radioimmunoassay to evaluate the effect of the insulin secretagogue nateglinide on plasma glycated insulin in Type 2 diabetes. Methods: Ten patients (5M/5F, age 57.8±1.9 years, HbA1c 7.6±0.5%, fasting plasma glucose 9.4±1.2millimols per litre, creatinine 81.6&pl...

ea0003p85 | Diabetes &amp; Metabolism | BES2002

Demonstration of diurnal variation of plasma glycated insulin in type 2 diabetes

Lindsay J , McKillop A , Mooney M , O'Harte F , Bell P , Flatt P

Aims: Increasing evidence supports the role of glycated insulin in the insulin resistant state of type 2 diabetes. We measured 24-hour profiles of plasma glycated insulin, using a novel radioimmunoassay, to evaluate the effects of meal stimulated insulin secretion and the fasting state on production of plasma glycated insulin in type 2 diabetes. Methods: Patients (n=6, HbA1c 7.2±0.6%, fasting plasma glucose 7.4±0.7 mmol l-1, BMI 35.7±3.5 kg m<su...